Jim Plante is recognized as the founder of the Foundation for Kidney Transplant Research. In starting the foundation, he acquired a multitude of patents to enable him to provide superior genetic testing based on his own research and proven methods. Most recently he became a member of the International Trade Advisory Committee. The appointment presents him with access to real opportunities to present real help with children and families that are at a greater risk of developing inherited diseases.
Reviewing His History
At the start of his career, he expanded Beltronics and provided wave radar safety systems. The systems along with new products he made available increase the profitability of the company. He has since followed proven strategies to increase the profits of a multitude of companies to present their investors with real results. His next project was SmartDrive Systems. This company venture has led the production of commercial vehicle safety programs.
The programs consisted of GPS, monitor drivers, and sensor-based platforms. The technology expanded the company’s workforce and increased the share value over 12,000 percent overall. This led him to one of his more recent projects called Pathway Genomics. The project presented more advancements in genetic testing and discovery.
Reviewing Pathway Genomics
Pathway Genomics was started as a way to find a better way to treat kidney-related illnesses that could lead to a fatality. His actions enabled him to discover ways to lower risks and increase the longevity of patients who are predisposed to inherited illnesses. This could include diabetes, cardiovascular disease, and obesity. It is through these explorations, that Plante made extraordinary achievements.
Since the success of Pathway Genomics, Plante has discovered more effective strategies for isolating these genetic conditions. He has gained better insight into how medications can treat the illnesses more effectively before they present real risks to the patients.
Today, Plante continues to work with the Pathway Genomics project as well as Thynk Capital. He has presented real developments in which biotechnological investors can capitalize on his research and generate higher returns on their investments. Investors who want to learn more about his more recent projects contact Mr. Plante right now.